{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:04:25Z","timestamp":1783101865971,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.mib.2023.102319","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:07:24Z","timestamp":1681517244000},"page":"102319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Targeting the gut microbiota in inflammatory bowel diseases: where are we?"],"prefix":"10.1016","volume":"74","author":[{"given":"Nicolas","family":"Benech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-1822","authenticated-orcid":false,"given":"Harry","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2023.102319_bib1","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2023.102319_bib2","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2023.102319_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.mib.2023.102319_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.mib.2023.102319_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nri.2017.7","article-title":"Dysbiosis and the immune system","volume":"17","author":"Levy","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.mib.2023.102319_bib6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/j.gastro.2019.11.294","article-title":"Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review","volume":"158","author":"Pittayanon","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mib.2023.102319_bib7","series-title":"Molecular Genetics of Inflammatory Bowel Disease","first-page":"347","article-title":"The gut microbiome in inflammatory bowel disease","author":"Lavelle","year":"2019"},{"key":"10.1016\/j.mib.2023.102319_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/mi.2016.75","article-title":"Mechanisms of inflammation-driven bacterial dysbiosis in the gut","volume":"10","author":"Zeng","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.mib.2023.102319_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9040697","article-title":"The role of Enterobacteriaceae in gut microbiota dysbiosis in inflammatory bowel diseases","volume":"9","author":"Baldelli","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.mib.2023.102319_sbref10","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mib.2023.102319_bib11","first-page":"331","article-title":"The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases","volume":"16","author":"Richard","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.mib.2023.102319_sbref12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.abd0919","article-title":"Debaryomyces is enriched in Crohn\u2019s disease intestinal tissue and impairs healing in mice","volume":"371","author":"Jain","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.mib.2023.102319_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41385-019-0250-5","article-title":"New insights into intestinal phages","volume":"13","author":"Sausset","year":"2020","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.mib.2023.102319_sbref14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","article-title":"Gut microbiota-derived metabolites as key actors in inflammatory bowel disease","volume":"17","author":"Lavelle","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.mib.2023.102319_bib15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/pr060470d","article-title":"Rapid and noninvasive metabonomic characterization of inflammatory bowel disease","volume":"6","author":"Marchesi","year":"2007","journal-title":"J Proteome Res"},{"key":"10.1016\/j.mib.2023.102319_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.829525","article-title":"The emerging role of bile acids in the pathogenesis of inflammatory bowel disease","volume":"13","author":"Thomas","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.mib.2023.102319_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41564-021-00970-4","article-title":"Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut","volume":"6","author":"Laursen","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.mib.2023.102319_bib18","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3748\/wjg.v22.i3.1078","article-title":"Role of antibiotics for treatment of inflammatory bowel disease","volume":"22","author":"Nitzan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mib.2023.102319_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ajg.2011.72","article-title":"Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mib.2023.102319_bib20","first-page":"513","article-title":"Antimycobacterial therapy in Crohn\u2019s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen","volume":"89","author":"Prantera","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mib.2023.102319_sbref21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2015.03.045","article-title":"Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis","volume":"149","author":"Rossen","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mib.2023.102319_sbref22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mib.2023.102319_bib23","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2023.102319_bib24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2018.20046","article-title":"Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial","volume":"321","author":"Costello","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.mib.2023.102319_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S2468-1253(21)00400-3","article-title":"Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Haifer","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.mib.2023.102319_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s12934-021-01513-6","article-title":"Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study","volume":"20","author":"Fang","year":"2021","journal-title":"Micro Cell Fact"},{"key":"10.1016\/j.mib.2023.102319_sbref27","doi-asserted-by":"crossref","DOI":"10.1186\/s40168-020-0792-5","article-title":"Fecal microbiota transplantation to maintain remission in Crohn\u2019s disease: a pilot randomized controlled study","volume":"8","author":"Sokol","year":"2020","journal-title":"Microbiome"},{"key":"10.1016\/j.mib.2023.102319_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2020.1854640","article-title":"Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis","volume":"12","author":"Green","year":"2020","journal-title":"Gut Microbes"},{"key":"10.1016\/j.mib.2023.102319_bib29","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41591-021-01399-2","article-title":"Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial","volume":"27","author":"Mocanu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.mib.2023.102319_bib30","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1136\/gutjnl-2022-327811","article-title":"Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial","volume":"71","author":"Kedia","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.mib.2023.102319_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cell.2019.01.001","article-title":"Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle","volume":"176","author":"Pasolli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.mib.2023.102319_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s12915-019-0667-z","article-title":"Multiple levels of the unknown in microbiome research","volume":"17","author":"Thomas","year":"2019","journal-title":"BMC Biol"},{"key":"10.1016\/j.mib.2023.102319_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.gastro.2020.07.048","article-title":"A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis","volume":"160","author":"Henn","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mib.2023.102319_bib34","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.cell.2022.07.003","article-title":"Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation","volume":"185","author":"Federici","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.mib.2023.102319_bib35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nm.4102","article-title":"CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands","volume":"22","author":"Lamas","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.mib.2023.102319_bib36","article-title":"Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases","author":"Michaudel","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.mib.2023.102319_bib37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ajg.2015.149","article-title":"Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation","volume":"110","author":"Kolho","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mib.2023.102319_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00188-17","article-title":"Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction","volume":"3","author":"Zhou","year":"2018","journal-title":"mSystems"},{"key":"10.1016\/j.mib.2023.102319_bib39","first-page":"978","article-title":"Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn\u2019s disease","volume":"20","author":"Rajca","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.mib.2023.102319_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ecco-jcc\/jjw136","article-title":"Microbial factors associated with postoperative Crohn\u2019s disease recurrence","volume":"11","author":"Wright","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.mib.2023.102319_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","article-title":"Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases","volume":"21","author":"Ananthakrishnan","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.mib.2023.102319_bib42","article-title":"Role of adherent and invasive Escherichia coli in Crohn\u2019s disease: lessons from the postoperative recurrence model","author":"Buisson","year":"2022","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.mib.2023.102319_bib43","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1136\/annrheumdis-2019-215258","article-title":"Specific changes in faecal microbiota are associated with familial Mediterranean fever","volume":"78","author":"Deshayes","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mib.2023.102319_bib44","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/mi.2016.18","article-title":"Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation","volume":"9","author":"J\u00f8rgensen","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.mib.2023.102319_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712915","article-title":"Gut microbiome and common variable immunodeficiency: few certainties and many outstanding questions","volume":"12","author":"Varricchi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.mib.2023.102319_bib46","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/j.gastro.2022.06.088","article-title":"Biogeographic variation and functional pathways of the gut microbiota in celiac disease","volume":"163","author":"Constante","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mib.2023.102319_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba0624","article-title":"Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation","volume":"12","author":"Lamas","year":"2020","journal-title":"Sci Transl Med"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527423000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527423000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:59:31Z","timestamp":1761285571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527423000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":47,"alternative-id":["S1369527423000565"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2023.102319","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the gut microbiota in inflammatory bowel diseases: where are we?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mib.2023.102319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102319"}}